Get the Stockscreener App
77.00
3.94%
2.92
After Hours:
77.19
0.19
+0.25%
Billiontoone Inc stock is traded at $77.00, with a volume of 236.52K.
It is up +3.94% in the last 24 hours and up +9.98% over the past month.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
See More
Previous Close:
$74.08
Open:
$74.46
24h Volume:
236.52K
Relative Volume:
0.90
Market Cap:
$3.54B
Revenue:
$305.11M
Net Income/Loss:
$-196.00K
P/E Ratio:
-11,846.15
EPS:
-0.0065
Net Cash Flow:
-
1W Performance:
+8.04%
1M Performance:
+9.98%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$72.29
$77.31
1-Week Range:
$70.70
$80.38
52-Week Range:
$61.96
$138.70
Billiontoone Inc Stock (BLLN) Company Profile
Name
Billiontoone Inc
Sector
Industry
Phone
650-460-2551
Address
1035 O'BRIEN DRIVE, MENLO PARK
Compare BLLN vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLLN
Billiontoone Inc
|
77.00 | 3.41B | 305.11M | -196.00K | 0 | -0.0065 |
TMO
Thermo Fisher Scientific Inc
|
490.77 | 182.14B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
187.15 | 134.43B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
575.72 | 45.40B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
112.98 | 32.27B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
302.32 | 29.62B | 3.17B | 642.63M | 516.49M | 10.77 |
Billiontoone Inc Stock (BLLN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-26 | Initiated | Guggenheim | Buy |
| Dec-01-25 | Initiated | BTIG Research | Buy |
| Dec-01-25 | Initiated | JP Morgan | Overweight |
| Dec-01-25 | Initiated | Jefferies | Hold |
| Dec-01-25 | Initiated | Piper Sandler | Overweight |
| Dec-01-25 | Initiated | Stifel | Buy |
| Dec-01-25 | Initiated | Wells Fargo | Equal Weight |
| Dec-01-25 | Initiated | William Blair | Outperform |
View All
Billiontoone Inc Stock (BLLN) Latest News
BillionToOne Inc (BLLN) Shares Up 3.33% on Mar 25 - GuruFocus
Why BillionToOne, Inc. Class A Shares Are Sinking - TipRanks
BillionToOne, Inc.(NasdaqGS: BLLN) added to S&P Global BMI Index - marketscreener.com
Top Billiontoone (BLLN) Competitors 2026 - MarketBeat
Piper Sandler reiterates BillionToOne stock rating on NIPT tech By Investing.com - Investing.com Nigeria
Piper Sandler reiterates BillionToOne stock rating on NIPT tech - Investing.com
Billiontoone (BLLN) Stock Trends and Sentiment 2026 $BLLN - MarketBeat
Billiontoone (BLLN) Stock Forecast and Price Target 2026 $BLLN - MarketBeat
BillionToOne (NASDAQ: BLLN) Shares Climb 8% Amid Strong Momentum in Precision Diagnostics Sector - International Business Times Australia
BTIG lowers BillionToOne stock price target on valuation multiples - Investing.com Nigeria
BillionToOne, Inc.: Fundamental Analysis and Financial Ratings | BLLN | US0901681058 - marketscreener.com
BillionToOne Inc (BLLN) Shares Up 6.14% on Mar 13 - GuruFocus
BillionToOne’s Single-Molecule Next-Generation Sequencing Platform Redefines Molecular Diagnostics for Prenatal and Oncology Care 404148 - Minichart
BillionToOne 10-K: Revenue $305.1M, EPS $0.14 - TradingView
Billiontoone (NASDAQ:BLLN) Hits New 1-Year LowHere's What Happened - MarketBeat
Analysts Offer Insights on Healthcare Companies: ARS Pharmaceuticals (SPRY), BillionToOne, Inc. Class A (BLLN) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Billiontoone, Inc. (NASDAQ:BLLN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
BillionToOne Medicare Win Puts North Star Economics In Focus - Yahoo Finance
BillionToOne Market Share Gains Raise Questions On Undervalued BLLN Stock - simplywall.st
BLLN (BillionToOne) PB Ratio : (As of Mar. 07, 2026) - GuruFocus
Wall Street Zen Upgrades Billiontoone (NASDAQ:BLLN) to "Buy" - MarketBeat
BillionToOne (BLLN) Turns Profitable As Q4 EPS And Margins Challenge Bearish Narratives - simplywall.st
BillionToOne: Delivering And Lagging At The Same Time (NASDAQ:BLLN) - Seeking Alpha
Analysts Are Bullish on These Healthcare Stocks: BillionToOne, Inc. Class A (BLLN), Concentra Group Holdings Parent, Inc. (CON) - The Globe and Mail
What Makes BillionToOne (BLLN) an Attractive Bet? - Yahoo Finance
BTIG Maintains Buy on BillionToOne, Inc. (BLLN) March 2026 - Meyka
Billiontoone (NASDAQ:BLLN) Sees Large Volume Increase on Better-Than-Expected Earnings - MarketBeat
BillionToOne Q4 2025 Results: Profit & Revenue Surpass ForecastsNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Assessing BillionToOne (BLLN) Valuation After Recent Share Price Volatility - simplywall.st
BillionToOne Q4 2025 slides: profitability achieved amid 113% revenue surge By Investing.com - Investing.com Nigeria
Wells Fargo & Company Has Lowered Expectations for Billiontoone (NASDAQ:BLLN) Stock Price - MarketBeat
BTIG lowers BillionToOne stock price target on valuation multiples By Investing.com - Investing.com India
Billiontoone's (BLLN) "Buy" Rating Reiterated at Guggenheim - MarketBeat
Billiontoone (NASDAQ:BLLN) Price Target Lowered to $140.00 at BTIG Research - MarketBeat
BLLN: BTIG Analyst Lowers Price Target Amid Maintained 'Buy' Rat - GuruFocus
BillionToOne Swings To Profit In Q4; Lifts FY26 Guidance - Nasdaq
Billiontoone (NASDAQ:BLLN) Announces Earnings Results - MarketBeat
Billiontoone Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: BillionToOne’s Q4 2025 sees robust growth, stock dips - Investing.com India
BillionToOne Q4 2025 slides: profitability achieved amid 113% revenue surge - Investing.com
BillionToOne (BLLN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
BillionToOne Raises 2026 Guidance, Aligns Incentive Plan - TipRanks
BillionToOne: Q4 Earnings Snapshot - marketscreener.com
BillionToOne Q4 Swings to Profit, Revenue Rises; Increases 2026 Revenue Guidance - marketscreener.com
(BLLN) BillionToOne Expects 2026 Revenue Range $430M-$445M, vs. FactSet Est of $405.1M - marketscreener.com
Earnings Flash (BLLN) BillionToOne Posts Q4 EPS $0.11, vs. FactSet Est of $0.06 - marketscreener.com
Earnings Flash (BLLN) BillionToOne, Inc. Reports Q4 Revenue $96.1M, vs. FactSet Est of $87.2M - marketscreener.com
BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance - GlobeNewswire
Billiontoone (NASDAQ:BLLN) Trading Down 5.7%Time to Sell? - MarketBeat
BillionToOne Inc (BLLN) Trading Down 6.28% on Mar 4 - GuruFocus
BillionToOne Stock at $89: Why a New $19.1 Million Position Could Matter Now - AOL.com
Billiontoone Inc Stock (BLLN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):